Viewing Study NCT00002332


Ignite Creation Date: 2025-12-24 @ 9:42 PM
Ignite Modification Date: 2025-12-27 @ 11:18 AM
Study NCT ID: NCT00002332
Status: COMPLETED
Last Update Posted: 2005-06-24
First Post: 1999-11-02
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: A Study of Timunox (Thymopentin) in HIV-Infected Patients Receiving Other Anti-HIV Drugs
Sponsor: Immunobiology Research Institute
Organization:

Study Overview

Official Title: Double-Blind Study of the Effect of Timunox (Thymopentin) on Lymphoproliferative Responses and Virus Load in HIV-Infected Subjects Receiving Nucleoside Analog Antiretroviral Therapy
Status: COMPLETED
Status Verified Date: 1995-12
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: To evaluate the mechanism whereby thymopentin appears to retard the progressive immune suppression attributable to HIV infection.
Detailed Description: Patients are randomized to receive subcutaneous thymopentin or placebo thrice weekly for 4 weeks.

Study Oversight

Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:

Secondary ID Infos

Secondary ID Type Domain Link View
07.32.039-94 None None View